KEEP OUT OF REACH OF CHILDREN KEEP OUT OF REACH OF CHILDREN

FOR ANIMAL TREATMENT ONLY FOR ANIMAL TREATMENT ONLY

OVURELIN OVURELIN
Gonadotrophin Releasing Hormone (GnRH) Sterile Injection Gonadotrophin Releasing Hormone (GnRH) Sterile Injection
DESCRIPTION DESCRIPTION
Ovurelin is a clear, colourless, sterile solution containing 100µg/mL Gonadorelin (as acetate) for Ovurelin is a clear, colourless, sterile solution containing 100µg/mL Gonadorelin (as acetate) for
use in the synchronisation of oestrus in combination with PGF2, treatment of anoestrus, use in the synchronisation of oestrus in combination with PGF2, treatment of anoestrus,
prevention of delayed ovulation and improvement of postpartum fertility and the treatment of prevention of delayed ovulation and improvement of postpartum fertility and the treatment of
cystic ovaries, in cattle. cystic ovaries, in cattle.
MODE OF ACTION MODE OF ACTION
Ovurelin Injection contains Gonadorelin, a decapeptide identical to the endogenous Ovurelin Injection contains Gonadorelin, a decapeptide identical to the endogenous
Gonadotropin Releasing Hormone (GnRH), which controls the production and secretion of Gonadotropin Releasing Hormone (GnRH), which controls the production and secretion of
Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) by the pituitary gland. Both Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) by the pituitary gland. Both
LH and FSH have a direct effect on the ovary: FSH stimulates follicle development, while LH LH and FSH have a direct effect on the ovary: FSH stimulates follicle development, while LH
induces ovulation and luteinization. induces ovulation and luteinization.
Injection of Ovurelin induces the simultaneous release of FSH and LH thereby stimulating the Injection of Ovurelin induces the simultaneous release of FSH and LH thereby stimulating the
maturation of ovarian follicles, ovulation and development of the corpus luteum. maturation of ovarian follicles, ovulation and development of the corpus luteum.
INDICATIONS INDICATIONS
1. Oestrus synchronisation 1. Oestrus synchronisation
Oestrus synchronisation is a procedure developed to synchronise ovulation for timed Oestrus synchronisation is a procedure developed to synchronise ovulation for timed
breeding. Procedures involving a combination of PGF2/GnRH have been found to be breeding. Procedures involving a combination of PGF2/GnRH have been found to be
superior in terms of pregnancy rate and calving to conception intervals in dairy cattle. Using superior in terms of pregnancy rate and calving to conception intervals in dairy cattle. Using
a combination of PGF2/GnRH also result in a more precise synchronisation hence a combination of PGF2/GnRH also result in a more precise synchronisation hence
allowing fixed-time insemination. Fixed-term insemination in turn allows insemination of allowing fixed-time insemination. Fixed-term insemination in turn allows insemination of
large groups of cows together, without the need for oestrus detection. large groups of cows together, without the need for oestrus detection.

The PGF2/GnRH procedure for dairy cattle reproductive management is as follows: The PGF2/GnRH procedure for dairy cattle reproductive management is as follows:
(i) Day 0 – GnRH administration: (i) Day 0 – GnRH administration:
GnRH induces ovulation and luteinisation of dominant follicles present at the time of GnRH induces ovulation and luteinisation of dominant follicles present at the time of
treatment and causes the smaller follicles to undergo atresia. A new follicular wave is treatment and causes the smaller follicles to undergo atresia. A new follicular wave is
subsequently recruited and a new dominant follicle gradually emerges. subsequently recruited and a new dominant follicle gradually emerges.
(ii) Day 7 – PGF2 administration: (ii) Day 7 – PGF2 administration:
7 days after the first treatment with GnRH, PGF2 is administered. Administration of 7 days after the first treatment with GnRH, PGF2 is administered. Administration of
PGF2 causes luteolysis of the GnRH induced corpus luteum. The new dominant follicle is PGF2 causes luteolysis of the GnRH induced corpus luteum. The new dominant follicle is
ready to ovulate 2 – 3 days later. ready to ovulate 2 – 3 days later.
(iii) Day 9 – GnRH administration: (iii) Day 9 – GnRH administration:
The second GnRH dose induces an LH surge, which further synchronises the dominant The second GnRH dose induces an LH surge, which further synchronises the dominant
follicle, resulting in ovulation of predictable timing, allowing fixed time insemination 8 – 24 follicle, resulting in ovulation of predictable timing, allowing fixed time insemination 8 – 24
hours later. hours later.
(iv) Insemination 8 – 24 hours after the second GnRH, regardless of the presence or (iv) Insemination 8 – 24 hours after the second GnRH, regardless of the presence or
absence of visible oestrus. absence of visible oestrus.
2. Treatment of Anoestrus 2. Treatment of Anoestrus
(i) Day 0 – GnRH administration and insertion of P4 device. (i) Day 0 – GnRH administration and insertion of P4 device.
(ii) Day 7 – PGF2 administration (ii) Day 7 – PGF2 administration
(iii) Day 7 – 9 AI to detected oestrus during next 72 hours. (iii) Day 7 – 9 AI to detected oestrus during next 72 hours.
(iv) Day 10 – GnRH administration and Fixed Time AI of all non-bred cows during the (iv) Day 10 – GnRH administration and Fixed Time AI of all non-bred cows during the
next 24 hours. next 24 hours.
3. Prevention of delayed ovulation 3. Prevention of delayed ovulation
Delayed ovulation can result in the reduction of the rate of conception due to asynchrony Delayed ovulation can result in the reduction of the rate of conception due to asynchrony
between ova and sperm at the time of artificial insemination (AI). between ova and sperm at the time of artificial insemination (AI).
Delayed ovulation can be prevented by the administration of Ovurelin, which stimulates the Delayed ovulation can be prevented by the administration of Ovurelin, which stimulates the
release of LH and hence induces ovulation. release of LH and hence induces ovulation.
4. Improvement of postpartum fertility 4. Improvement of postpartum fertility
It is important that normal ovarian cyclical activity resume in the early post-partum period to It is important that normal ovarian cyclical activity resume in the early post-partum period to
minimise the calving to conception interval or ‘days open’. minimise the calving to conception interval or ‘days open’.
Ovurelin given in the first 40 days of the postpartum period may initiate the ovarian cyclical Ovurelin given in the first 40 days of the postpartum period may initiate the ovarian cyclical
activity to resume, and reduce the incidence of postpartum infertility in cows. activity to resume, and reduce the incidence of postpartum infertility in cows.
5. Treatment of cystic ovaries 5. Treatment of cystic ovaries
Cystic ovaries are an infertility problem in dairy cattle, which may be of single or multiple Cystic ovaries are an infertility problem in dairy cattle, which may be of single or multiple
and of follicular or luteal origin. Clinical signs of ovarian cysts include irregular oestrus and of follicular or luteal origin. Clinical signs of ovarian cysts include irregular oestrus
cycles, anoestrus and nymphomania. Ovarian cysts can be diagnosed by rectal palpation cycles, anoestrus and nymphomania. Ovarian cysts can be diagnosed by rectal palpation
of the structures on one or both ovaries. Treatment of cystic ovaries with Ovurelin may of the structures on one or both ovaries. Treatment of cystic ovaries with Ovurelin may
result in the recommencement of normal cyclical activity, through the response of ovarian result in the recommencement of normal cyclical activity, through the response of ovarian
cysts to the released LH induced by Ovurelin. Ovurelin given in the first 40 days of the cysts to the released LH induced by Ovurelin. Ovurelin given in the first 40 days of the
postpartum period may initiate the ovarian cyclical activity to resume, and reduce the postpartum period may initiate the ovarian cyclical activity to resume, and reduce the
incidence of postpartum infertility in cows. incidence of postpartum infertility in cows.
DIRECTIONS FOR USE DIRECTIONS FOR USE
For intramuscular injection to the anterior half of the neck. For intramuscular injection to the anterior half of the neck.
Dose rate Dose rate
Oestrus synchronisation: Oestrus synchronisation:
Day 0 1mL Ovurelin (100µg Gonadorelin) Day 0 1mL Ovurelin (100µg Gonadorelin)
Day 7 2mL Ovuprost (500µg Cloprostenol) Day 7 2mL Ovuprost (500µg Cloprostenol)
Day 9 1mL Ovurelin (100µg Gonadorelin) Day 9 1mL Ovurelin (100µg Gonadorelin)
Insemination 8 – 24 hours after 2nd injection of Ovurelin Insemination 8 – 24 hours after 2nd injection of Ovurelin
Treatment of anoestrus Treatment of anoestrus
Prosynch (Hybrid) Programme Prosynch (FTAI) Programme Prosynch (Hybrid) Programme Prosynch (FTAI) Programme
Day 1 1mL Ovurelin (+P4) Day 1 1mL Ovurelin (+P4) Day 1 1mL Ovurelin (+P4) Day 1 1mL Ovurelin (+P4)
Day 7 2mL Ovuprost (remove P4) Day 7 2mL Ovuprost (remove P4) Day 7 2mL Ovuprost (remove P4) Day 7 2mL Ovuprost (remove P4)
Day 7 – 9 Mate to detected oestrus. Day 9 1mL Ovurelin Day 7 – 9 Mate to detected oestrus. Day 9 1mL Ovurelin
Day 10 1mL Ovurelin to unmated cows FTAI between 16 – 20 hours Day 10 1mL Ovurelin to unmated cows FTAI between 16 – 20 hours
FTAI within 24 hours FTAI within 24 hours
Prevention of delayed ovulation: 2.5mL Ovurelin (250µg Gonadorelin) Prevention of delayed ovulation: 2.5mL Ovurelin (250µg Gonadorelin)
Improvement of postpartum fertility: 2.5mL Ovurelin (250µg Gonadorelin) Improvement of postpartum fertility: 2.5mL Ovurelin (250µg Gonadorelin)
Cystic ovaries: 5mL Ovurelin (500µg Gonadorelin) Cystic ovaries: 5mL Ovurelin (500µg Gonadorelin)
WITHHOLDING PERIODS WITHHOLDING PERIODS
Milk and Meat: Nil. Milk and Meat: Nil.
STORAGE STORAGE
Store below 25°C (room temperature). Protect from light. Use within 28 days of broaching the Store below 25°C (room temperature). Protect from light. Use within 28 days of broaching the
vial or flexipack when used in a sterile manner, or discard the unused portion. vial or flexipack when used in a sterile manner, or discard the unused portion.
DISPOSAL DISPOSAL
Preferably dispose of the product by use. Otherwise dispose of product and packaging in an Preferably dispose of the product by use. Otherwise dispose of product and packaging in an
approved landfill or other approved facility. approved landfill or other approved facility.
PRESENTATION PRESENTATION
20mL glass vial and 100mL plastic flexipack. 20mL glass vial and 100mL plastic flexipack.
Prescription Animal Remedy (P.A.R) Class I Prescription Animal Remedy (P.A.R) Class I
For use only under the authority or prescription of a veterinarian. For use only under the authority or prescription of a veterinarian.
Registered pursuant to the ACVM Act 1997, No. A9949. Registered pursuant to the ACVM Act 1997, No. A9949.
See www.nzfsa.govt.nz/acvm/ for registration conditions. See www.nzfsa.govt.nz/acvm/ for registration conditions.

Bayer New Zealand Limited Bayer New Zealand Limited